PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
|
|
- Andra Ray
- 5 years ago
- Views:
Transcription
1 MONDAY, JUNE 3, :30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments to Daily Practice Track(s): Central Nervous System Tumors; Fostering Moral Resilience: Steps You Can Take to Manage Moral Distress and Burnout in Oncology Track(s): Professional Development; Ethics Acute Myeloid Leukemia in Older Adults: More Versus Less Therapy Track(s): Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant; Disparities/Health Equity; Geriatric Oncology; Management of Uncommon and Rare Breast Cancers Track(s): Breast Cancer Obtaining Consent in Pediatric Oncology: New and Ongoing Challenges Track(s): Pediatric Oncology; Clinical Trials; Ethics; Health Services Research, Clinical Informatics, and Quality of Care The Impact of Big Data Research on Practice, Policy, and Patient Care Track(s): Health Services Research, Clinical Informatics, and Quality of Care; Clinical Trials; Disparities/ Health Equity; Value Value-Added Decisions in Oncology: Searching High and Low Using Clinical Vignettes Track(s): Care Delivery and Practice Management; Gastrointestinal (Colorectal) Cancer; Genitourinary (Prostate) Cancer; Lung Cancer; Value Meet the Professor: Can We Cure Myeloproliferative Neoplasms? Track(s): Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant; Symptoms and Survivorship Meet the Professors: Surgery, Liver-Directed Treatment, or Systematic Therapy Where Are the Boundaries for Hepatic Metastases? Developmental Therapeutics and Tumor Biology (Nonimmuno) Track(s): Developmental Therapeutics and Translational Research Genitourinary (Nonprostate) Cancer Lung Cancer Non-Small Cell Metastatic Track(s): Lung Cancer Page 1 of 6
2 8:00 AM - 11:00 AM S S 9:45 AM - 10:45 AM 9:45 AM - 11:00 AM S S 9:45 AM - 11:15 AM 9:45 AM - 12:45 PM S Sarcoma Track(s): Sarcoma Track(s): Gastrointestinal (Colorectal) Cancer Track(s): Gastrointestinal (Colorectal) Cancer Gastrointestinal (Noncolorectal) Cancer Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Track(s): Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Hematologic Malignancies Lymphoma and Chronic Lymphocytic Leukemia Hematologic Malignancies Plasma Cell Dyscrasia Track(s): Hematologic Malignancies Plasma Cell Dyscrasia Managing Early Relapse in Multiple Myeloma Track(s): Hematologic Malignancies Plasma Cell Dyscrasia Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal? Track(s): Central Nervous System Tumors; Navigating a New Cancer Diagnosis: Guiding Communication and Education Track(s): Pediatric Oncology; Disparities/Health Equity; Health Services Research, Clinical Informatics, and Quality of Care Clinical Controversies: Are Geriatric Syndromes in the Domain of the Oncologist? Track(s): Geriatric Oncology; Care Delivery and Practice Management; Meet the Professors: How to Write an Outstanding Manuscript Track(s): Professional Development Special Clinical Science Symposium #3 ASCO/American Association for Cancer Research (AACR) Joint Session: Conducting Histology- Agnostic Clinical Trials Breast Cancer Local/Regional/Adjuvant Track(s): Breast Cancer Cancer Prevention, Hereditary Genetics, and Epidemiology Page 2 of 6
3 11:30 AM - 12:15 PM AWARD LECTURE 11:30 AM - 12:30 PM S 11:30 AM - 12:45 PM S S 11:30 AM - 1:00 PM S 12:00 PM - 1:00 PM ANNUAL BUSINESS MEETING 1:15 PM - 2:00 PM Ellen L. Stovall Award and Lecture for Advancement of Cancer Survivorship Care Track(s): Emerging New Standards of Care for Advanced Kidney Cancer ; Clinical Trials; Immunotherapy Implementing Palliative and Supportive Care in Cancer Care Worldwide Track(s): Global Health; Academic-Community Partnerships: Approaches to Engagement Track(s): Care Delivery and Practice Management; Health Services Research, Clinical Informatics, and Quality of Care Beyond Checkpoint Blockade: An Update on Engineered T-Cell Therapy and Neoantigen Vaccine Application Track(s): Developmental Immunotherapy and Tumor Immunobiology Oncology Reimbursement Reform: Are Changes on the Horizon for Promotion of Higher Value Care? Track(s): Health Services Research, Clinical Informatics, and Quality of Care; Care Delivery and Practice Management; Value The More Things Change: Ovarian Cancer Edition Track(s): Gynecologic Cancer Meet the Professor: The Future of Immunotherapy in Non Small Cell Lung Cancer Track(s): Lung Cancer; Developmental Immunotherapy and Tumor Immunobiology; Immunotherapy Meet the Professors: Peptide Receptor Radionuclide Therapy and Systemic Treatment in Gastrointestinal Neuroendocrine Tumors Sarcoma Clinical Science Symposium Track(s): Sarcoma Gastrointestinal (Colorectal) Cancer Track(s): Gastrointestinal (Colorectal) Cancer Hematologic Malignancies Lymphoma and Chronic Lymphocytic Leukemia ASCO Annual Business Meeting (ASCO Members Only) AWARD LECTURE ASCO/American Cancer Society Award and Lecture Page 3 of 6
4 1:15 PM - 2:15 PM S 1:15 PM - 2:30 PM S S 1:15 PM - 2:45 PM Clinical Conundrums in the Management of Rectal Cancer Track(s): Gastrointestinal (Colorectal) Cancer Controversies in Breast Cancer Adjuvant Therapy Track(s): Breast Cancer; Geriatric Oncology Immunotherapies in Thymic Malignancies, Mesothelioma, and Small Cell Carcinoma Track(s): Lung Cancer; Immunotherapy International Collaborations and Regional Challenges in Sarcoma Track(s): Sarcoma; Clinical Trials; Disparities/Health Equity; Global Health The Elephant in the Room: Addressing Depression and Suicide Among Oncology Providers Track(s): Professional Development; Care Delivery and Practice Management Why Doesn't Checkpoint Inhibitor Immunotherapy Work for All Patients? Track(s): Developmental Immunotherapy and Tumor Immunobiology Meet the Professors: Chemotherapy, Radiation, Surgery, and Immunotherapy Optimizing Sequence and Combination of Multidisciplinary Care for Borderline Resectable Pancreatic Cancer (BRPC) Meet the Professors: Treatment Advances and Opportunities in Testicular Cancer Education Research Clinical Science Symposium Track(s): Professional Development 1:15 PM - 4:15 PM S S Hematologic Malignancies Plasma Cell Dyscrasia Track(s): Hematologic Malignancies Plasma Cell Dyscrasia Central Nervous System Tumors Track(s): Central Nervous System Tumors Gynecologic Cancer Track(s): Gynecologic Cancer Cancer Prevention, Hereditary Genetics, and Epidemiology Genitourinary (Nonprostate) Cancer Melanoma/Skin Cancers Track(s): Melanoma/Skin Cancers Track(s): Page 4 of 6
5 3:00 PM - 4:00 PM S 3:00 PM - 4:15 PM Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions Track(s): Care Delivery and Practice Management; Disparities/Health Equity; Immunotherapy; Multidisciplinary Care in Challenging Sarcoma Scenarios Track(s): Sarcoma S Clinical Controversies in Relapsed Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy 3:00 PM - 4:30 PM Employing Big Data and Predictive Analytics to Determine Patient Risk in Oncology Track(s): Care Delivery and Practice Management; Health Services Research, Clinical Informatics, and Quality of Care; Value How to Measure Quality in Value-Based Systems Track(s): Health Services Research, Clinical Informatics, and Quality of Care; Disparities/Health Equity; Value Local-Regionally Advanced Non Small Cell Lung Cancer: Advances in Multimodality Treatment Track(s): Lung Cancer; Immunotherapy Molecular Profiling in Breast Cancer: Past, Present, and Future Track(s): Breast Cancer; Cancer Prevention, Hereditary Genetics, and Epidemiology Meet the Professors: Treatment of Rare but Critical Mutations in Non Small Cell Lung Cancer Track(s): Lung Cancer; Geriatric Oncology Clinical Science Symposium Track(s): Geriatric Oncology; Disparities/Health Equity 4:30 PM - 6:00 PM S 4:45 PM - 5:30 PM Gastrointestinal (Noncolorectal) Cancer Cancer Prevention, Hereditary Genetics, and Epidemiology Genitourinary (Nonprostate) Cancer Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Track(s): Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Melanoma/Skin Cancers Track(s): Melanoma/Skin Cancers Track(s): AWARD LECTURE B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology Track(s): Geriatric Oncology Page 5 of 6
6 4:45 PM - 5:45 PM S 4:45 PM - 6:00 PM S Financial Assistance for Participation in Clinical Trials: What Works Best for Patients? Track(s): Health Services Research, Clinical Informatics, and Quality of Care; Care Delivery and Practice Management; Clinical Trials; Disparities/Health Equity Recognizing, Understanding, and Overcoming Toxicities From Immune Checkpoint Inhibitors Track(s): Developmental Immunotherapy and Tumor Immunobiology; Gastrointestinal (Noncolorectal) Cancer; Debate: This House Believes FLOT Is the Standard Treatment for Fit Patients With T3N1 GEJ Adenocarcinoma New Options in Metastatic Squamous Cell Carcinoma Track(s): Lung Cancer; Meet the Professors: Offering Patients With Relapsed and Refractory Follicular Lymphoma the Best Choice in a Sea of Novel Options Page 6 of 6
Ludwig Presence at 2016 ASCO Annual Meeting
Ludwig Scientist(s) Affiliation(s) Session and Presentation Time Location Track Session Type/Title Presentation and/or Abstract Title Friday, June 3, 2016 Luisa Lina Villa Ludwig Sao Paulo 1:00pm - 3:15pm
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationFACULTY MEMBERSHIP APPLICATION Tulane Cancer Center
FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,
More informationDuke at. American Society of Clinical Oncology Chicago, Illinois
Duke at American Society of Clinical Oncology 2017 Chicago, Illinois Duke Medicine Divisions of Hematology Medical Oncology and Hematologic Malignancy & Cellular Therapy Cordially invite you to the Duke
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationDEPARTMENT OF ONCOLOGY ELECTIVE
DEPARTMENT OF ONCOLOGY ELECTIVE 2015-2016 www.uwo.ca/oncology Oncology Elective Program Administrator: Ms. Kimberly Trudgeon Room A4-901C (Admin) LHSC London Regional Cancer Centre (Victoria Campus) Phone:
More information2008 Oncology Pharmacy Preparatory Review Course Learning Objectives
2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationCurriculum: Goals and Objectives Department of Medicine Harbor-UCLA Medical Center
MEDICAL ONCOLOGY AND HEMATOLOGY (R2, R3) A. The PURPOSE of this rotation is to afford medical residents a broad clinical and training experience in the clinical diagnosis and management of common adult
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationAmerican Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG.
American Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG www.cancer.net www.cancer.net Tell your patients about the ASCO doctor-approved PATIENT INFORMATION WEBSITE Cancer.Net brings the
More informationRoche Investor Relations ASCO Planner 2016
Roche Investor Relations ASCO Planner 2016 Friday, June 3 Session Title: Pediatric Oncology I Date: Fri, June 3 Location: S504 Time: 3:00 PM - 6:00 PM Speaker Name: Veronique Minard-Colin 5:12 PM - 5:24
More information2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives
2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives Acute Leukemia/Tumor Lysis Syndrome John M. Valgus, Pharm.D., BCOP Hematology/Oncology Specialist University of North
More informationAre the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Clinical practice guidelines Definition > Systemically developed statements
More informationOnline/Self study courses
Online/Self study courses This list of CE offerings is not all inclusive. ONCC accepts many other accredited CE programs for ILNA Points. If you would like to know the applicability of a program not listed,
More information2 Diagnosis and Staging of Cancer 2.1 Pathophysiology of cancer 2.2 Classification and staging 2.3 Diagnostic measures for specific cancer types
Oncology Nursing Sub-Specialty Module Reference: Gobel B. M., Triest-Robertson S. & Vogel W.H. (Eds). (205). Advanced Oncology Nursing Certificate Review and Resources Manual. Pittsburgh: Oncology Nursing
More informationOnline/Self-study courses
Online/Self-study courses This list of CE offerings is not all inclusive. ONCC accepts many other accredited CE programs for ILNA Points. If you would like to know the applicability of a program not listed,
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationTUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital)
Legend: Keynote Educational Meet the Expert (MTE) Paediatric Psycho-Oncology () Opening/Closing Award Session Free Paper Session (FPS) Session Satellite SIOPe GA SIOP ABM Late Breaker Session Networking
More informationCancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 19-21, 2016
Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC 20037 October 19-21, 2016 Wednesday, October 19, 2016 7:30 8:30 AM Registration
More informationCASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES
ESMO Preceptorship GI Tumours Singapore 20-22 nd October CASE DISCUSSION ON GASTRIC CANCER BASED ON ESMO GUIDELINES Professor. J-Y. Douillard MD PhD ESMO Chief Medical Officer CLINICAL PRACTICE GUIDELINES
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationPrecision CAR T Cell Therapeutics. Carl June October 15, 2018
Precision CAR T Cell Therapeutics Carl June October 15, 2018 Disclosure Information Carl June I have the following financial relationships to disclose: Consultant for: Novartis, Immune Design, Viracta,
More informationAnnual Flash Report (unaudited) Fiscal Year ended March 31, 2017
Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationRadiation Oncology Study Guide
Radiation Oncology Study Guide For the Initial CertificationQualifying (Computer-Based) Examination General and Radiation Oncology This examination is designed to assess your understanding of the entire
More informationReprogramming Tumor Associated Dendritic Cells for Immunotherapy
Reprogramming Tumor Associated Dendritic Cells for Immunotherapy Edgar Engleman, M.D. Professor of Pathology and Medicine Stanford University Disclosures: Founder of Dendreon, a biotechnology company that
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationCancer Awareness Talk ICPAK 2014
Cancer Awareness Talk ICPAK 2014 F. Chite Asirwa, MB ChB. MD. MSc. Internist. Medical Oncologist & Hematologist Asst. Professor of Medicine Division of Hematology/Oncology Indiana University Email: fasirwa@iu.edu
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationAvastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
More informationAnnual Report. Cape Cod Hospital and Falmouth Hospital Regional Cancer Network Expert physicians. Quality hospitals. Superior care.
Annual Report Cape Cod Hospital and Falmouth Hospital Regional Cancer Network 2013 Expert physicians. Quality hospitals. Superior care. Cape Cod Hospital s Davenport- Mugar Hematology/Oncology Center and
More informationCancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development MicroTek Training Center Washington, DC October 17 19, 2018
Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development MicroTek Training Center Washington, DC October 17 19, 2018 Wednesday, October 17, 2018 8:00 8:30 AM Registration and Continental
More informationTUESDAY, 18th OCTOBER, 2016 / DAY -2
Legend: Keynote Educational PODC Symposium Meet the Expert (MTE) Paediatric Psycho-Oncology () Opening/Closing Award Session Free Paper Session (FPS) Session Satellite Symposium SIOPe GA SIOP ABM Late
More informationMedical Marijuana Use in Patients with History of SCCHN Treated with Radiotherapy
HEALTH SERVICES RESEARCH Assessment the Impact of Real-time Tumor Tracking & Reduced Planning Target Volume Margins on Quality-of-Life in Prostate Cancer Patients Treatment with Intensity Modulated Radiotherapy
More informationDevelopment status of OPDIVO (nivolumab) 1
August 1, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Filing Approved (US) Non-small cell lung
More informationRadiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationMerck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
News Release Merck KGaA, Darmstadt, Germany Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor Relations:
More informationCSQI BACKGROUNDER What is The Cancer Quality Council of Ontario (CQCO)? What does CQCO do? What is the Cancer System Quality Index?
CSQI BACKGROUNDER What is The Cancer Quality Council of Ontario (CQCO)? Established in 2002 by the Ministry of Health and Long-Term Care (MOHLTC), the Cancer Quality Council of Ontario (CQCO) is an arm
More informationPosters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationa resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
More informationFighting Cancer with Data: Perspectives on MD Anderson Moon Shot Program
Fighting Cancer with Data: Perspectives on MD Anderson Moon Shot Program Joxel Garcia, MD, MBA Executive Director, Cancer Prevention and Control Platform Member, Moon Shots Program Leadership Team The
More informationMaking a Difference. Highest quality care. Education. Research. Innovation. OUR MISSION:
Making a Difference Highest quality care. Education. Research. Innovation. OUR MISSION: To deliver world-class care on a daily basis to our patients using the most advanced technologies available. To conduct
More informationNRG ONCOLOGY SEMIANNUAL MEETING PRELIMINARY AGENDA Phoenix Convention Center Phoenix, Arizona February 7 9, 2019
Thursday, February 7, 2019 6:30 am 7:30 am Introduction to Clinical Trials: Principles of Clinical Trial Management Breakfast 7:00 am 8:30 am Symposium Breakfast 7:00 am 6:00 pm Registration/CME/Information
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationAmerican Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG.
American Society of Clinical Oncology PATIENT EDUCATION MATERIALS CATALOG www.cancer.net www.cancer.net Tell your patients about the doctor-approved PATIENT INFORMATION WEBSITE FROM ASCO Cancer.Net brings
More informationMEASURE SPECIFICATIONS
QOPI REPTING REGISTRY (QCDR) 2018 QOPI 5 QOPI 11 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Combination chemotherapy
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationQuarterly Health Topics Series Sanofi s Vision in Oncology. Wednesday, June 13, 2018
Quarterly Health Topics Series Sanofi s Vision in Oncology Wednesday, June 13, 2018 Agenda Sanofi s Vision in Oncology Welcome coffee Advances in Cancer Care Jorge Insuasty, Global Head of Development
More informationMEASURE SPECIFICATIONS
QOPI REPTING REGISTRY (QCDR) 2018 QOPI5 Title Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Description Percentage
More information:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B
04-10-2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture
More informationis time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
More informationTrial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor
Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,
More informationDevelopment status of OPDIVO (nivolumab) 1
November 2, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Approved Approved(EU) Non-small cell
More informationIndiana University Hematology Oncology Fellows Research Interest
Coming into fellowship, my interest was in thoracic oncology. I was interested in targeted therapy in lung cancer and immunotherapy. My current research project is looking into combining immunotherapy
More information2016 CANCER PROGRAM REPORT. Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL
2016 CANCER PROGRAM REPORT Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL 32401 850.769.1511 www.baymedical.org 2016 Cancer Program Report Bay Medical Sacred Heart provides
More informationCODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
More informationQOPI and the Rapid Learning Oncology Care System. Copyright 2011 American Society of Clinical Oncology. All rights reserved 1
QOPI and the Rapid Learning Oncology Care System Copyright 2011 American Society of Clinical Oncology. All rights reserved 1 Program Description Quality improvement program for outpatient hematologyoncology
More informationASCO 2018 Summary of Presentation. May 16, 2018
ASCO 2018 Summary of May 16, 2018 ASCO: Accepted s Oral presentations DS-8201 Pexidartinib Poster discussions U3-1402 Quizartinib DS-3032 Poster presentations Trial-in-Progress DS-8201 U3-1402 DS-1062
More informationScarce Resources are best Applied to Prevention The Anti Argument
Scarce Resources are best Applied to Prevention The Anti Argument Lawrence N Shulman, MD Director, Center for Global Cancer Medicine Abramson Cancer Center, University of Pennsylvania Senior Oncology Advisor
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationUCI. Anti-Cancer Challenge Impact report. #weareanticancer
UCI Anti-Cancer Challenge 2017 Impact report #weareanticancer Your support of the UCI Anti-Cancer Challenge is planting the seeds from which UCI research will grow to improve cancer therapies! As Orange
More informationCancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 25-27, 2017
Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC 20037 October 25-27, 2017 Wednesday, October 25, 2017 7:30 8:30 AM Registration
More informationTUMOR M ARKERS MARKERS
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
More informationQuality of End-of-Life Care in Patients with Hematologic Malignancies: A Retrospective Cohort Study
Quality of End-of-Life Care in Patients with Hematologic Malignancies: A Retrospective Cohort Study David Hui, Neha Didwaniya, Marieberta Vidal, Seong Hoon Shin, Gary Chisholm, Joyce Roquemore, Eduardo
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationAnnounce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017
AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,
More informationTable E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths
RSNA, 2016 10.1148/radiol.2016152472 Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths Observed/Expected No. of Deaths Observed/Expected
More informationProgram Schedule Clinical Multidisciplinary Hematology & Oncology: The 16 th Annual Review
Program Schedule Clinical Multidisciplinary Hematology & Oncology: The 16 th Annual Review Friday, February 15, 2019 6:45 a.m. Registration, Breakfast and Exhibits 7:30 a.m. Welcome and Introductions SESSION
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More informationSteamboat Springs, Colorado. January 15-18, 2016
Friday, January 15, 2016 Registration: Begins at 2:00 pm Plenary Session: 4:00 pm - 6:00 pm 14 th Oncology Update: Advances and Controversies Steamboat Springs, Colorado January 15-18, 2016 Current Status
More informationONCOLOGY AND MALIGNANT HEMATOLOGY REVIEW CONFERENCE
ASCO 2018 ONCOLOGY AND MALIGNANT HEMATOLOGY REVIEW CONFERENCE September 28, 2018 Eastern Area Health Education Center 2600 W. Arlington Blvd. Jointly provided by: East Carolina University Department of
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More information2016 Oncology Institute Annual Report
2016 Oncology Institute Annual Report Message from the Cancer Committee: On behalf of the Cancer Committee of The Methodist Hospitals, we are pleased to present to you our 2016 Oncology Institute Annual
More informationQUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS
QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors
More informationCurrent and Future Treatment Options for Glioblastoma
Current and Future Treatment Options for Glioblastoma Santosh Kesari, MD, PhD, FANA, FAAN Chair, Department of Translational Neurosciences and Neurotherapeutics John Wayne Cancer Institute & Pacific Neuroscience
More informationIdentifying and counting people living with treatable but not curable cancer
Identifying and counting people living with treatable but not curable cancer Rachel White Joanna Pethick, Archie Macnair, Gregory Fallica, Jennifer Than and Jane Maher September 2018 Who are the people
More informationCurrent Fellow Projects
INDIANA UNIVERSITY Hematology Oncology Fellowship IU HEMATOLOGY ONCOLOGY FELLOWSHIP PROGRAM Division of Hematology Oncology IU department of Medicine 535 Barnhill Drive, Room 473 Indianapolis, IN 46202
More informationMEDICAL ONCOLOGY Maintenance of Certification (MOC) Examination Blueprint
MEDICAL ONCOLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Medical Oncology MOC exam blueprint Based on feedback from physicians that MOC assessments
More informationYour contact. Merck and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody
Your contact Merck Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 News Release Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160 May
More informationSupplementary Materials for
Supplementary Materials for A Clinical Trial for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes Not Eligible for Standard Clinical Trials Table of Contents Content Page Supplementary
More informationRecent Advances in Gastrointestinal Cancers
Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:
More informationOncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R
Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R 2 0 1 2 Objectives Discuss Diagnostic and staging strategies in oncology Know
More informationCODING PRIMARY SITE. Nadya Dimitrova
CODING PRIMARY SITE Nadya Dimitrova OUTLINE What is coding and why do we need it? ICD-10 and ICD-O ICD-O-3 Topography coding rules ICD-O-3 online WHAT IS CODING AND WHY DO WE NEED IT? Coding: to assign
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More informationThe Latest in Non-Hodgkin Lymphoma News From ASCO
Patient Power Knowledge. Confidence. Hope. The Latest in Non-Hodgkin Lymphoma News From ASCO John Leonard, MD Associate Dean for Clinical Research Weill Cornell Medical College Please remember the opinions
More informationManaging Older Patients With Lymphoma and Multiple Myeloma
2006 ONS Congress Webcast Evaluation Form Managing Older Patients With Lymphoma and Multiple Myeloma Session length: 1 hour, 45 minutes Contact hours: 1.5 Pharmacology hours offered: 15 minutes How to
More informationOctober 17 20, 2018 New York City. An International Congress on Lymphoma, Myeloma, and Leukemia Disorders
An International Congress on Lymphoma, Myeloma, and Leukemia Disorders NEW DAY! New Approaches in Acute Leukemias and Hematologic Malignancies Wednesday, October 17 October 17 20, 2018 New York City lymphomaandmyeloma.com
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationNOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)
Item 18-13c NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May 2013 BREAST CANCER MCN: Breast Disease: Breast Document ready to circulate lead to be discussed
More informationPLEASE NOTE THE PROGRAM BEGINS ON FRIDAY MORNING, JANUARY 12, Steamboat Springs, Colorado. January 12-15, 2018
PLEASE NOTE THE PROGRAM BEGINS ON FRIDAY MORNING, JANUARY 12, 2018 16 th Oncology Update: Advances and Controversies Steamboat Springs, Colorado January 12-15, 2018 Friday, January 12, 2018 Registration:
More information